Type 1 diabetes (T1D) is characterized by complete or near complete absence of endogenous insulin secretion resulting in the need to deliver exogenous insulin in an individualized, precise manner.1 Current clinically approved technologies to replace insulin result in unacceptable risk for hypoglycemia, hyperglycemia, and glycemic variability (GV).2 Changes in plasma glucose concentration are more pronounced in T1D, occur rapidly and are related to food intake, physical activity and imprecise insulin delivery. The maturation of technologies such as continuous glucose monitoring (CGM), continuous subcutaneous insulin infusion (CSII) or insulin pump, rapid acting insulin analogs and closed-loop control (CLC) algorithms that deliver insulin based on CGM data processing has resulted in CLC therapy becoming an area of active research with rapid therapeutic translation to clinical practice. 4 Current CLC studies show significant improvement in hypoglycemia and a bigger burden of hyperglycemia relative to time spent in hypoglycemic range. 4,5 Occurrence of hyper and hypoglycemia with current CLC, the burden associated with current CLC and limitations of eligible populations to use current technologies indicate the need for further innovation. Important variables in this context with potentially significant effect sizes are physical activity and meals. Significant efforts have been made to model the aforementioned parameters and understand their effect on glucose-insulin dynamics by incorporating/adapting them into CLC simulators. 6,7 Even though the day to day effect of physical activity on glucose status poses major challenges for T1D, limited research in this area has been conducted. 8 Since obesity and type 2 diabetes mellitus (T2D), 2 major disorders of whole body energy balance, continue to rise worldwide, most research to-date regarding physical activity capture device use has been pursued in these 2 disorders.9,10 T2D is characterized by hyperglycemia for a significant proportion of the day with the majority of such subjects having limited hypoglycemia
AbstractPhysical activity is an important determinant of glucose variability in type 1 diabetes (T1D). It has been incorporated as a nonglucose input into closed-loop control (CLC) protocols for T1D during the last 4 years mainly by 3 research groups in single center based controlled clinical trials involving a maximum of 18 subjects in any 1 study. Although physical activity data capture may have clinical benefit in patients with T1D by impacting cardiovascular fitness and optimal body weight achievement and maintenance, limited number of such studies have been conducted to date. Clinical trial registries provide information about a single small sample size 2 center prospective study incorporating physical activity data input to modulate closed-loop control in T1D that are seeking to build on prior studies. We expect an increase in such studies especially since the NIH has expanded support of this type of research with additional grants starting in the second hal...